Lannett Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANNETT, and what generic and branded alternatives to LANNETT drugs are available?
LANNETT has one hundred and thirty-two approved drugs.
There is one tentative approval on LANNETT drugs.
Summary for Lannett
US Patents: | 0 |
Tradenames: | 97 |
Ingredients: | 94 |
NDAs: | 132 |
Patent Litigation for Lannett: | See patent lawsuits for Lannett |
PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lannett Co Inc | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 211622-001 | Jun 6, 2023 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Lannett Co Inc | PREDNISOLONE | prednisolone | SYRUP;ORAL | 040775-001 | Sep 21, 2007 | AA | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Lannett Co Inc | DEXMETHYLPHENIDATE HYDROCHLORIDE | dexmethylphenidate hydrochloride | TABLET;ORAL | 209468-003 | Sep 25, 2017 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Here is a list of applicants with similar names.